Jornay PM 40mg to Ritalin Conversion
Do not substitute Jornay PM for immediate-release methylphenidate on a milligram-per-milligram basis—discontinue Jornay PM 40 mg and initiate immediate-release Ritalin at 5 mg twice daily (morning and noon), then titrate upward based on clinical response.
Rationale for Non-Equivalence
The FDA label for Jornay PM explicitly states: "Do not substitute JORNAY PM for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles from JORNAY PM and may have different methylphenidate base composition" 1. This is critical—Jornay PM is a delayed-release, extended-release formulation taken at night (6:30-9:30 PM) that delivers methylphenidate with a unique biphasic profile designed to provide symptom control the following morning and throughout the day. Immediate-release Ritalin has completely different absorption kinetics with peak effects at 1-2 hours and duration of 3-4 hours.
Recommended Conversion Algorithm
Step 1: Discontinue Jornay PM
- Stop the evening dose of Jornay PM 40 mg completely
- Allow 24 hours washout before initiating IR methylphenidate
Step 2: Initiate IR Methylphenidate (Ritalin)
- Starting dose: 5 mg twice daily (morning after breakfast and noon after lunch) 2
- This conservative starting approach is recommended regardless of prior long-acting formulation dose
Step 3: Titration Schedule
- Increase by 5-10 mg per dose weekly until optimal symptom control is achieved 2
- Monitor response using parent and teacher rating scales at each increment
- Assess for side effects systematically (appetite, sleep, headaches, irritability, tics)
Step 4: Determine Final Dosing
- Maximum total daily dose: 60 mg (per PDR recommendations) 2
- Most patients require 2-3 times daily dosing with IR formulations
- Typical effective range: 10-20 mg per dose, 2-3 times daily
- A third afternoon dose (around 4 PM) may be added if coverage is needed for homework/evening activities 2
Clinical Considerations
Why not use a 1:1 conversion? Research demonstrates that different methylphenidate formulations have vastly different pharmacokinetic profiles. Studies show that extended-release formulations like MPH-SR produce lower peak plasma concentrations and different absorption slopes compared to IR formulations 2, 3. The 40 mg Jornay PM dose delivers methylphenidate over 12+ hours with delayed onset; attempting to match this with IR dosing requires individualized titration, not mathematical conversion.
Common pitfall: Clinicians sometimes assume that the total daily dose should remain constant when switching formulations. This is incorrect and potentially dangerous—always start low with IR formulations and titrate to effect 1.
Monitoring requirements during transition:
- Baseline and follow-up vital signs (blood pressure, pulse, height, weight) 2
- Weekly assessment during titration phase
- Specific questioning about known side effects: insomnia, anorexia, headaches, social withdrawal, tics, weight loss 2
Alternative approach if twice-daily dosing is problematic: Once the optimal IR dose is determined through titration, consider converting to a sustained-release formulation by adding morning and noon IR doses together 2. However, this secondary conversion should only occur after establishing the effective IR dose, not as a direct switch from Jornay PM.
Duration of action differences: IR methylphenidate provides 3-4 hours of coverage per dose, requiring multiple daily administrations. Patients previously on once-nightly Jornay PM will need to adjust to this dosing schedule, which may affect school administration and compliance 4, 5.